Dulcosoft

Quick links to important sections

Dulcosoft

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dulcosoft

Quick Facts

Property Description
Active ingredient Macrogol 4000 (Polyethylene Glycol)
Form Powder for Oral Solution, Oral Solution
Pharmacological class Osmotic Laxative
General purpose Softening of hard stools
Origin Synthetic Polymer Compound

What Type of Medicine is Dulcosoft and Its Core Component?

Dulcosoft is a medicinal agent classified as an osmotic laxative, primarily used to facilitate comfortable bowel movements. Its sole active ingredient is Macrogol 4000, which is a high molecular weight form of Polyethylene Glycol (PEG). This compound is a synthetic polymer that is chemically inert, meaning it is not broken down or significantly absorbed by the body. Macrogol-based laxatives are a standard and clinically recognized treatment option for constipation.

The Non-Stimulant Osmotic Laxative Mechanism

The general therapeutic purpose of Dulcosoft is to provide effective relief by physically softening dry, hard stools through its osmotic effect. Macrogol 4000 utilizes its high water-binding capacity to draw and retain water within the colon, preventing the water from being reabsorbed by the body. This process ensures that the stool mass is fully hydrated and increased in volume. Macrogol provides effective symptomatic relief due to its non-degradable nature and ability to normalize stool consistency. This physical mode of action offers a gentle approach to normalizing bowel function.

Available Pharmaceutical Forms and Compositional Characteristics

Dulcosoft is supplied for oral administration in two main dosage forms: a Powder for oral solution and a ready-to-use Oral solution. Both preparations contain only the single active ingredient, Macrogol 4000. These formulations are typically manufactured to be sugar-free, gluten-free, and lactose-free, ensuring wide tolerance and minimal impact on specific dietary requirements, making the product suitable for various patient groups, including those managing diabetes.

Regulatory References

  1. NICE Guideline: Constipation in children and young people

What side effects are possible with Dulcosoft?

Possible side effects and safety information

Official regulatory documents classify the possible adverse reactions of Macrogol 4000 (the active ingredient in Dulcosoft) across three main System-Organ Classes: Gastrointestinal disorders, Immune system disorders, and Metabolism and Nutrition Disorders.

Frequency-Classified Adverse Reactions

The majority of documented effects are gastrointestinal and are generally described as minor and transitory. These effects typically disappear upon temporary interruption or reduction of the dose, a temporal pattern noted in prescribing information.

Classification Examples of Reactions
Common (up to 1 in 10) Abdominal pain and distension, Diarrhoea, Nausea.
Uncommon (up to 1 in 100) Vomiting, Urgency to defecate, Faecal incontinence.
Very Rare (Adults) Severe hypersensitivity reactions, including Anaphylactic shock and Quincke oedema (Angioedema).
Not Known Electrolyte disorders (e.g., Hyponatraemia), Dehydration, Erythema.

Key Safety Constraints and Considerations

The medicine is officially contraindicated in cases of intestinal obstruction, digestive perforation or risk of, toxic megacolon, or severe inflammatory bowel disease (such as Crohn’s disease or ulcerative colitis). These safety restrictions emphasize the importance of ruling out underlying organic disorders prior to initiating treatment.

Safety notes specify that elderly patients and individuals with impaired renal or hepatic function are particularly prone to electrolyte disorders and dehydration if severe diarrhoea occurs. In the paediatric population, the officially documented maximum duration of treatment must not exceed 3 months due to lack of long-term data. Furthermore, Macrogol 4000 may cause a transient reduction in the absorption of other co-administered medicinal products, which could potentially lead to decreased efficacy of those products.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Macrogol 4000 (Dulcosoft) is officially documented to lead to an exaggeration of its osmotic effect, resulting in specific clinical manifestations and requiring mandatory emergency actions as outlined by regulatory authorities.

Documented Overdose Manifestations and Risks

Manifestation Type Officially Documented Statement
Primary Symptoms Excessive diarrhea and accompanying abdominal pain [Macrogol SmPC content].
Life-Threatening Risks Severe dehydration and critical electrolyte imbalances, which can potentially lead to secondary symptoms such as confusion or seizures [FDA Drug Labeling; NIH/NCBI StatPearls].

Required Emergency Actions

In the event of a suspected overdose, regulatory information mandates specific, immediate action. There is no specific antidote known for Macrogol 4000 overdose. Treatment is restricted to symptomatic and supportive care aimed at correcting the physiological disturbances.

  • Mandatory Action: The official prescribing information explicitly requires individuals to seek immediate medical help or contact a Poison Control Center right away when overdose is suspected [FDA Drug Labeling].
  • Management Focus: The required supportive measures involve the close monitoring of fluid status and laboratory values to actively correct any fluid or electrolyte deficiencies that have arisen from excessive fluid loss.

Seeking immediate medical attention is necessary due to the risk of severe dehydration and its potentially serious systemic complications, which require professional intervention.

Therapeutic Uses of Dulcosoft

Quick Facts

  • Addresses: Symptoms of occasional constipation.
  • Therapeutic effect: Facilitates bowel movements.
  • Primary function: Supports stool softening.

Dulcosoft provides symptomatic relief for occasional constipation. Its core purpose is to assist in the management of irregular or infrequent bowel movements, which is a key therapeutic domain.

In this context, the product is indicated for the softening of hard stools. Softening hard stools is a crucial step in easing the process of defecation and supporting more comfortable passage of material through the intestine.

Dulcosoft is appropriate for use in adults and children (typically aged 8 years and over, depending on the specific formulation) experiencing these symptoms. Its main ingredient is Macrogol 4000 (a type of polyethylene glycol).

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Dulcosoft

Dulcosoft, containing the active substance macrogol 4000 (polyethylene glycol), is officially indicated for use by adults and adolescents.

Age-Related Eligibility

  • Allowed: Use is generally established for adults and children aged 8 years and above (powder formulation). Certain regional liquid formulations may permit use from 6 months of age, but medical advice is often required for children under 8 years.
  • Not Recommended: The powder formulation is not recommended for children below the age of 8 years without consultation from a healthcare professional.

Contraindicated Populations (Must Not Use)

Official regulatory documents stipulate that this medicine must not be used by individuals with the following conditions:

  • Hypersensitivity or allergy to the active substance, Macrogol 4000, or any of the product's excipients.
  • Severe inflammatory bowel diseases, such as Crohn's disease or ulcerative colitis.
  • Gastrointestinal perforation or an increased risk of perforation.
  • Intestinal obstruction (ileus), a suspicion of obstruction, or symptomatic narrowing of the bowel (stenosis).
  • Painful abdominal syndromes of unknown cause.

Use During Pregnancy and Lactation

Dulcosoft can be taken during both pregnancy and breastfeeding as the systemic absorption of macrogol 4000 is negligible. However, official labeling advises individuals who are pregnant or breastfeeding to consult a doctor or pharmacist before using the medicine.

What should I know about interactions with other medicines?

Dulcosoft, which contains the active ingredient macrogol 4000, is generally considered to have a low potential for significant systemic drug-to-drug interactions due to its minimal absorption into the body.

However, there are documented considerations related to its use with certain substance categories and drug classes:

Interacting Product Category Potential Effect Important Condition/Note
Starch-Based Food Thickeners Reduced efficacy of the thickener Should be considered in patients with swallowing difficulties who require thickened fluids, as macrogol can counteract the thickening agent’s action.
Diuretics (e.g., water tablets) Increased risk of electrolyte imbalance Caution is advised in patients taking diuretics, especially in cases of diarrhea and/or vomiting, due to the potential for excessive fluid and electrolyte loss. Monitoring of electrolyte levels may be necessary.

Because macrogol 4000 acts in the intestine primarily by increasing osmotic pressure, it may transiently modify the intestinal absorption of other medicines taken at the same time. This effect may be more relevant for medicines that have a narrow therapeutic range or a short half-life. It is important to inform a healthcare provider or pharmacist about all other medicines, supplements, or herbal products being taken to assess for any potential for reduced effectiveness.

Mechanism of Action

The mechanism of action for Macrogol 4000 is unique as it is physicochemical and does not rely on binding to biological targets like receptors or enzymes. The entire action is localized to the gastrointestinal lumen.

The Macrogol 4000 polymer acts as an osmotic agent within the large intestine. It strongly attracts and retains water molecules through hydrogen bonding, establishing a sustained osmotic gradient that prevents the colonic mucosa from reabsorbing fluid. This mechanism directly alters colonic lumen fluid homeostasis, resulting in the softening and bulking of the faecal mass.

The significant increase in the volume and hydration of the faecal mass serves as a mechanical physiological stimulus. This bulk causes the colon wall to distend, which naturally activates and enhances the bowel's intrinsic smooth muscle contractions (peristalsis). This secondary effect promotes the transit of the softened matter through the modulation of colonic peristalsis.

Dosage and Administration Information

How to Use Dulcosoft (Macrogol 4000) — Administration Guidelines

This guide outlines the instructions for the administration and dosing of Dulcosoft (Macrogol 4000). It does not provide medical advice or therapeutic indications.


Administration Scope

Field Instruction
Route of administration Oral Use (by mouth).
Dosing schedule Adults and Children ge 8 years: Usually 1 to 2 sachets (10g to 20g Macrogol 4000) or 20-40 mL of Oral Solution daily. The dose should be adjusted to achieve regular soft stools.
Timing in relation to meals Can be taken before or after food.
Preparation requirements Powder: Dissolve each sachet in 125 mL of water or other liquid (e.g., juice, tea) immediately before taking it. Liquid Solution: Mix the prescribed dose directly with a drink (e.g., 150 mL).
Age-group rules Children ge 8 years: Treatment should not exceed 3 months. Children < 8 years: Use is generally not recommended unless under medical advice.
Missed-dose rules Do not take a double dose to make up for a missed dose.

Resulting Procedural Structure

The protocol requires the user to prepare the dose, take it orally once daily, and adjust it based on response. The effect typically occurs within 24 to 48 hours.

Step sequence:

  • Prepare the Dose: Dissolve the sachet in 125 mL of liquid or measure the appropriate volume of solution and mix it into a drink.
  • Administer: Take the prepared solution orally, preferably as a single dose in the morning.
  • Adjust: Titrate the daily dose (up to 2 sachets/40 mL) to maintain the desired soft stool consistency.

This structured approach defines the required preparation, timing, and dose adjustment.

Recent Clinical Evidence

Dulcosoft: Recent Clinical Evidence

The research landscape for Macrogol 4000, the active ingredient in Dulcosoft, consists primarily of evidence from Randomized Controlled Trials (RCTs) and systematic reviews. These studies focus on the measurement of outcomes related to functional constipation.


Evidence for Chronic Idiopathic and Functional Constipation

The evidence body relates to the ingredient's evaluation in conditions characterized by infrequent and hard stools. Researchers conducted numerous short- and intermediate-term controlled trials to evaluate how symptoms change. Outcomes research examined variables such as the mean number of Spontaneous Complete Bowel Movements per week and the monitoring of Stool Consistency using standardized scales. Studies reported patterns observed in the trials, such as shifts in measured bowel movements and a change toward a softer stool consistency when compared to placebo groups.

Key Study Comparisons and Measurement Endpoints

Research compared Macrogol 4000 with either a placebo or other osmotic laxatives like lactulose. These trials assessed endpoints that reflect daily functioning. Findings describe patterns of measured stool consistency endpoints between the agents, contributing to understanding symptom patterns in the observed populations.


Evidence in Special Populations and Long-Term Use

Macrogol 4000 was studied in research that included children, including infants and toddlers, as well as older adults. Findings for these groups provide information on how patients reported their experience. The research describes short-term changes, but findings are limited to the populations studied and do not determine individual response. The majority of primary RCTs used to evaluate the ingredient explored short-term changes, typically four weeks to six months, though observational settings include data for longer observation periods.


What Research Gaps and Uncertainties Exist

Specific research limitations exist. Follow-up durations were limited in the core randomized trials, meaning long-term effects are not fully established. Data for certain groups remain insufficient, particularly controlled data for use in children extending beyond the common regulatory recommendation of a three-month period. Comparative evidence is also lacking for direct head-to-head trials against all other available osmotic or bulk-forming laxatives.

Key Studies & References Constipation in children and young people: diagnosis and management (NICE Guideline NG62)

Frequently Asked Questions (FAQ)

Common questions about Dulcosoft (FAQ)


Q: How quickly does Dulcosoft typically start working?

Studies and official information indicate that the effects of Macrogol 4000 are typically apparent within 24 to 48 hours following the first administration. This timeframe is consistent with the product's gentle, osmotic mode of action.


Q: Can Dulcosoft be used long-term, or only for short periods?

Regulatory product information notes that use should generally not exceed 30 days, unless a prolonged period is suggested by a healthcare provider. For use in children aged 8 years and above, regulatory documents stipulate that treatment should not exceed 3 months due to limited long-term safety data in this population.


Q: Can I mix Dulcosoft with other liquids besides water?

The official administration guidelines state that the powder formulation can be dissolved in water or other liquids, such as fruit juice or tea, immediately before taking it.


Q: Can Dulcosoft be taken with food, or does it need to be on an empty stomach?

According to the official product information, it can be taken before or after consuming food. There are no specific dietary restrictions regarding the timing of administration relative to meals.


Q: What should I do if I accidentally take more Dulcosoft than intended?

Official safety notes state that taking excessive doses is likely to cause symptoms such as diarrhoea, abdominal pain, and abdominal distension (bloating). These effects typically resolve when the dose is interrupted or reduced. Regulatory guidance indicates that contacting a healthcare professional or poisons information center is warranted in this circumstance.


Q: Can I split the daily amount of Dulcosoft into two smaller doses?

Official administration instructions recommend taking the full daily dose, preferably as a single dose in the morning. The labeling indicates this single-dose method is generally preferred.


Q: Is Dulcosoft suitable for use during pregnancy or breastfeeding?

Regulatory information indicates that Macrogol 4000 can be taken during both pregnancy and breastfeeding due to its minimal systemic absorption by the body. Official labeling suggests individuals who are pregnant or breastfeeding seek consultation with a healthcare provider.


Q: Does Dulcosoft affect the body's electrolyte balance?

Macrogol 4000 formulations without electrolytes are generally not associated with clinically relevant electrolyte disturbances. Safety notes acknowledge that patients prone to electrolyte imbalance may require caution, especially if severe diarrhoea is experienced.


Q: Is there a different version of Dulcosoft available for infants?

In some regions, Macrogol 4000 is available in different dosage strengths, such as 4g sachets or liquid formulations. These may be used for younger children, generally aged 6 months to 8 years, and use in this population often occurs following consultation with a healthcare professional.


Q: Can I take Dulcosoft if I have a history of kidney problems?

Regulatory safety notes indicate that individuals with impaired renal function are typically advised to consult a healthcare provider before initiating treatment, due to a risk of electrolyte imbalance if severe diarrhoea occurs.


Q: Is Dulcosoft sugar-free or suitable for people with diabetes?

The product is generally formulated to be sugar-free and is described in official sources as suitable for use by people with diabetes. Its non-absorbable nature suggests a minimal impact on blood sugar levels.


Q: Why does Dulcosoft have different names in different countries?

The use of different names is a result of pharmaceutical companies employing different brand names in various international markets. However, the active ingredient, Macrogol 4000, remains the same across these different products.


Q: Can Dulcosoft cause gas or bloating?

Regulatory documents list flatulence (gas), abdominal pain, and abdominal distension (bloating) as common, possible side effects. These effects are generally described as transient.


Q: Are there any reported studies on the use of Dulcosoft in the elderly?

Yes, regulatory documents and supporting evidence confirm that Macrogol 4000 has been studied for use in older adults as a treatment option for constipation. It is noted to be generally well-tolerated in this population.


Q: Are there any dietary restrictions required while using Dulcosoft?

Regulatory instructions do not impose specific dietary restrictions. The product is recommended to be taken in addition to maintaining a healthy lifestyle and diet, which supports normal bowel function.


Q: Can taking too much Dulcosoft cause diarrhea?

Official safety notes state that taking excessive doses is likely to cause symptoms such as diarrhoea, abdominal pain, and abdominal distension. These effects typically resolve when the dose is reduced.


Q: Does Dulcosoft contain sodium or potassium?

The active ingredient, Macrogol 4000, is often formulated without added electrolytes like sodium or potassium. This distinguishes it from other macrogol products that contain these specific salts.


Q: Is the long-term safety profile of Dulcosoft documented in regulatory sources?

Regulatory evidence indicates that the majority of randomized controlled trials used short follow-up durations. This means that while short- and intermediate-term effects are established, the full long-term safety profile is not comprehensively documented in core trial data.


Q: Why is Dulcosoft commonly recommended for chronic constipation?

It is commonly recommended as a first-line treatment because of its purely physical, osmotic mode of action. Since the product is not absorbed by the body, it offers a descriptive physical approach to softening hard stools and supporting bowel function.


Q: What is the difference between an osmotic agent and a bulk-forming agent?

An osmotic agent like Macrogol 4000 works by drawing water into the stool, which increases the fluid content and softens the mass. In contrast, bulk-forming agents work by increasing the physical mass of the stool through the addition of fiber or similar substances.


Q: Can Dulcosoft cause allergic reactions, and what are the signs?

Regulatory safety information reports rare hypersensitivity reactions, including severe types like anaphylactic shock, angioedema (swelling of the face or throat), urticaria (hives), and rash. The guidance indicates that if these signs occur, discontinuation of use and seeking medical help are warranted.


Q: Is there a maximum number of consecutive days Dulcosoft can be used?

Official instructions advise that use should not exceed 30 days. This limit is noted unless a longer period of use is specifically suggested by a healthcare professional.


Q: Can Dulcosoft be used before a colonoscopy preparation?

Macrogol-based formulations are widely used in clinical settings for bowel preparation prior to medical procedures such as a colonoscopy. This is due to the ingredient's ability to clear the digestive tract.


Q: Can I take Dulcosoft if I am already taking other daily medications?

Regulatory information notes that Macrogol 4000 may transiently modify the absorption of other concurrently administered oral medicines due to its presence in the gut. Official information suggests that a healthcare provider be informed about all current medications to assess for potential effects.


Q: What are the typical signs that Dulcosoft is working correctly?

The primary goal of the treatment is defined as the achievement of regular, softened stools. Successfully adjusting the dose to meet this goal is the typical sign that the product is working correctly for the individual.


Q: Does Dulcosoft have any known interactions with herbal supplements?

Official information indicates that a healthcare provider or pharmacist should be informed about all co-administered medicines, supplements, or herbal products to allow for assessment of potential for reduced effectiveness due to Macrogol’s physical mode of action.

How should Dulcosoft be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory information defines specific conditions for storing and disposing of this medication to ensure its stability and safe use.

Storage Conditions

Requirement Specification
Temperature Store below 25°C. Do not store above 25°C.
Environment Keep in a cool and dry place. Avoid damp or hot areas, such as bathrooms, sinks, or window sills.
Protection Store in the original container to protect the product from light.
Child Safety Keep the medicine out of the reach and sight of children.

Stability and Disposal

Requirement Specification
Opened Oral Solution Discard any remaining oral solution after 6 weeks of first opening the bottle.
Disposal Rule Do not dispose of the product in household trash or wastewater. Return expired, damaged, or unused medicine to a pharmacist for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dulcosoft found in:

A-Z Index: